Stay ahead of regulatory change and position TPRM as competitive advantage
2026 outlook
Navigating Third-Party Risk in the Pharmaceutical and Life Sciences Sector
What’s in this guidebook from Ethixbase360:
Since the release of the 2025 outlook, the regulatory and enforcement landscape has continued to shift. Pharmaceutical and life sciences companies face sustained regulatory scrutiny, expanding ESG obligations and intensifying geopolitical pressure on global supply chains. The 2026 edition reflects these developments, examining how regulatory expectations are rising and how enforcement activity continues to evolve across jurisdictions.
Against this backdrop, pharmaceutical and life sciences organizations must balance rigorous compliance demands with the need to remain agile and competitive. Third-party relationships sit at the center of this challenge. Extensive networks of external partners support every stage of the journey from discovery to market, but they also extend risk well beyond organizational boundaries. When third-party risk is not managed effectively, the consequences can include regulatory breaches, operational disruption, reputational harm and escalating costs.
Ethixbase360’s “Pharma & Life Sciences 2026 Outlook” delivers a clear view of the sector’s most material third-party risk exposures, the regulatory direction of travel and the operational capabilities required to manage risk at scale in an increasingly complex environment.
Inside the 2026 edition you’ll find:
- Enforcement updates under the FCPA, with heightened expectations around demonstrable program effectiveness.
- Practical implications of the adopted Corporate Sustainability Due Diligence Directive (CSDDD), alongside expanding ESG-related enforcement and disclosure requirements
- Evolving trade and forced-labor controls, including developments under the Uyghur Forced Labor Prevention Act (UFLPA) and tightening parallel import regimes.
- Sector-specific exposure across API sourcing, contract manufacturing, data integrity and cross-border distribution networks.
- Resilience strategies for scaling third-party risk programs, including risk tiering, continuous monitoring, defensible due diligence and AI-assisted workflows supported by human oversight.
- The business case for mature TPRM, linking effective third-party governance to investor confidence, M&A readiness, operational agility and brand protection.
Designed for compliance, legal, procurement and risk leaders, this outlook equips organizations to embed greater visibility, accountability and resilience across extended third-party ecosystems.
About Ethixbase360
With Ethixbase360, organizations can operationalize ownership transparency by integrating UBO into third-party risk management and sanctions compliance within a single, defensible framework.
